Holen Sie sich die Stockscreener-App
3.98
2.45%
-0.10
Handel nachbörslich:
4.03
0.05
+1.26%
Schlusskurs vom Vortag:
$4.08
Offen:
$4.04
24-Stunden-Volumen:
2.35M
Relative Volume:
0.61
Marktkapitalisierung:
$647.46M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
99.50
EPS:
0.04
Netto-Cashflow:
$146.36M
1W Leistung:
+18.10%
1M Leistung:
+14.70%
6M Leistung:
+427.29%
1J Leistung:
-13.10%
1-Tages-Spanne:
$3.94
$4.1295
1-Wochen-Bereich:
$3.94
$5.78
52-Wochen-Spanne:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Vergleichen Sie IRWD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.98 | 663.73M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
126.85 | 55.38B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.37 | 50.23B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.04 | 44.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.51 | 37.17B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.83 | 21.69B | 3.08B | 1.24B | 1.07B | 25.61 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-09 | Eingeleitet | Jefferies | Buy |
| 2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-02 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Eingeleitet | Northland Capital | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
| 2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
| 2017-04-07 | Bestätigt | Mizuho | Buy |
| 2017-02-22 | Bestätigt | Barclays | Equal Weight |
| 2016-11-04 | Bestätigt | Mizuho | Buy |
| 2016-10-24 | Bestätigt | Wedbush | Neutral |
| 2016-10-10 | Bestätigt | Mizuho | Buy |
| 2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
Ironwood stock rises 27% on upbeat revenue guidance for 2026 - MSN
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating - MarketBeat
5 Small Drug Stocks to Buy as Industry Recovery Picks Up - Yahoo Finance
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Craig Hallum - MarketBeat
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 32% Share Price Rise - 富途牛牛
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry - simplywall.st
Citizens Upgrades Ironwood Pharmaceuticals (IRWD) - Nasdaq
Wells Fargo Raises Target Price for IRWD to $5.00 Maintaining Eq - GuruFocus
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 - Finviz
Wells Fargo & Company Forecasts Strong Price Appreciation for Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock - MarketBeat
Ironwood Pharmaceuticals Inc. (IRWD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
The Five-year Loss for Ironwood Pharmaceuticals (NASDAQ:IRWD) Shareholders Likely Driven by Its Shrinking Earnings - 富途牛牛
Ironwood Pharmaceuticals (IRWD) Upgraded to Market Outperform by Citizens | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED) - Benzinga
Craig-Hallum Boosts Ironwood (IRWD) Rating with Optimistic Outlo - GuruFocus
Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift - TechStock²
Ironwood Pharmaceuticals stock price target raised to $5 by Wells Fargo - Investing.com Canada
Citizens upgrades Ironwood Pharmaceuticals stock rating on LINZESS strength By Investing.com - Investing.com Canada
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Nasdaq Futures Pipeline Depth - Kalkine Media
Promising Pharmaceutical Stocks To ConsiderJanuary 2nd - MarketBeat
Ironwood Pharmaceuticals Surges on Linzess Sales Boost - StocksToTrade
Ironwood hits 52-week high as AbbVie-partnered Linzess boosts 2026 outlook - MSN
Ironwood Pharmaceuticals’ Stock Surges as Higher Linzess Sales Drive Market Excitement - timothysykes.com
Ironwood Pharma leaps on 2025/2026 guidance - The Pharma Letter
Ironwood backs FY25 revenue view $290M-$310M, consensus $306.97M - Yahoo Finance
Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Ironwood Pharmaceuticals: Market Response to Legal Settlement - StocksToTrade
Ironwood Pharma (IRWD) Surges on Strong FY26 Guidance and Pipeli - GuruFocus
Stock soars at Boston biotech after it cuts price of IBS drug - The Business Journals
Ironwood Pharmaceuticals Stock (IRWD) Opinions on 2026 Financial Guidance - Quiver Quantitative
Ironwood Pharmaceuticals Stock Soars as Drug-Price Cut Boosts Prospects for 2026 - Barron's
Ironwood Pharmaceuticals stock soars on strong 2026 guidance By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals stock soars on strong 2026 guidance - Investing.com
Stock Traders Buy High Volume of Ironwood Pharmaceuticals Call Options (NASDAQ:IRWD) - MarketBeat
Ironwood Reaffirms FY2025 Revenue Outlook, Sees Growth In FY2026; Stock Surges - RTTNews
Ironwood Pharmaceuticals (NASDAQ:IRWD) Hits New 12-Month HighHere's Why - MarketBeat
Ironwood Pharmaceuticals, Baidu, Vertiv Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
Why did Ironwood Pharmaceuticals stock skyrocket today? - MSN
Ironwood Pharma Stock Rallies On Strong 2026 OutlookIronwood Pharmaceuticals (NASDAQ:IRWD) - Benzinga
Why Did Ironwood Pharmaceuticals Stock Skyrocket Today? - Stocktwits
Ironwood’s Recent Move: A Catalyst for Change? - timothysykes.com
Why Is IRWD Stock Soaring Over 30% Premarket? 2026 Revenue Outlook Beats Estimates - Tokenist
Ironwood (IRWD) Focuses on Financial Growth and Drug Development - GuruFocus
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Year 2025 and Provides Earnings Guidance for Year 2026 - MarketScreener
Ironwood Pharmaceuticals (IRWD) Projects Strong Revenue Growth f - GuruFocus
Ironwood beats on 2026 outlook thanks to AbbVie-partnered Linzess - MSN
Ironwood Pharma Provides FY26 Outlook, Maintains Full Year Outlook - Nasdaq
Ironwood forecasts 2026 LINZESS sales to exceed $1.1 billion - Investing.com
Ironwood forecasts 2026 LINZESS sales to exceed $1.1 billion By Investing.com - Investing.com UK
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.41%
1.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):